Personalized cancer medicine for non-small cell lung cancer

• Project/Area Number: 22590864
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Respiratory organ internal medicine
• Research Institution: Shimane University
• Principal Investigator: ISOBE Takeshi 島根大学, 医学部, 教授 (70284198)
• Project Period (FY): 2010 – 2012
• Project Status: Completed (Fiscal Year 2012)
• Budget Amount: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000); Fiscal Year 2012: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2011: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000); Fiscal Year 2010: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
• Keywords: 非閉塞性肺疾患 / 肺線維症 / 呼吸器感染症 / 肺癌 / 個別化治療 / 非閉塞性肺疾患癌

Research Abstract

We developed a reliable, reproducible, and simple orthotopic model for human lung cancer cell line using nude mice, multiple models with different biologic and clinical phenotypes may allow a better understanding of the behavior and treatment effects. We also showed correlation of the biomarker expression between biopsy specimens and surgical specimens assessed by IHC. Finally, we conducted a phase I/II clinical study of combination chemotherapy with EGFR-tyrosine kinase inhibitor and cytotoxic agent for recurrent lung cancer.These results lead to individualized chemotherapy and benefit patients with advanced non-small-cell lung cancer.

Research Products

• [Presentation] Phase I/II and pharmacological clinical study of combination chemotherapy with irinotecan and erlotinib for recurrent lung cancer (2013)
  • Author(s): Okimoto T, Hotta T, Koba N, NishikawaE, Maehara M, Miura K, Karino F, Iwamoto S, Tsubata Y, Hamaguchi S, Honda T, Mitsuhiro T, Ohe M, Sutani A, Kuraki T,Takeyama H, M, Hamada A, Isobe T
  • Organizer: Aamerican Thoracic Society
  • Place of Presentation: Philadelphia(米国)
• [Presentation] Effect of erlotinib on the pharmacokinetics of irinotecan and its metabolites in an animal model: a drug-drug interaction study (2013)
  • Author(s): Sanematsu E, Isobe T
  • Organizer: American Association for Cancer Research
  • Place of Presentation: Washington（米国）
• [Presentation] Phase I/II And Pharmacological Clinical Study Of Combination Chemotherapy With Irinotecan And Erlotinib For Recurrent Lung Cancer (2013)
  • Author(s): Okimoto T, Isobe T
  • Organizer: American Thoracic Society
  • Place of Presentation: Philadelphia（米国）
• [Presentation] Evaluation of novel orthotopic nude mouse models for human small cell lung cancer (2012)
  • Author(s): Isobe T , Nishio Y, Fuchita H, Koba N,Nishikawa E, Hotta T, Okimoto T, Iwamoto S, Karino F, Tsubata Y, Miura K, Tada M, Suzuki T, Honda T, Hamaguchi S, Hanada M, Ohe M, Sutani A, Kuraki T, Takeyama H, Onn A, Roy S. Herbst
  • Organizer: Japanese Cancer Society
  • Place of Presentation: Royton Sapporo(北海道)
• [Presentation] Comparison of biomarker expression between biopsy and surgical specimens of non-small-cell lung cancer. Assessement by immunohistochemical staining. (2012)
  • Author(s): Okimoto T, Tsubata Y, Sutani A, Fuchita H, Koba N, Nishikawa E, Hotta T, Okimoto T, Iwamoto S, Karino F, Miura K, Tada M, Suzuki T, Honda T, Hamaguchi S, Ohe M, Sutani A, Kuraki T, Isobe T
  • Organizer: American Thoracic Sosiety
  • Place of Presentation: SanFrancisco(米国)
• [Presentation] Comparison of biomarker expression between biopsy and surgical specimens of non-small-cell lung cancer. Assessement by immunohistochemical staining. (2012)
  • Author(s): Okimoto, Isobe T
  • Organizer: American Thoracic Society
  • Place of Presentation: San Francisco（米国）